Company / Operating Cash Flow
Vertex Pharmaceuticals Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$3.6B
FY2025
5-year range
-$492.6M / $4.1B
FY2021-FY2025
Trend
+837.2%
vs FY2024
Sector context
#11 of 216
Health Care
What the data says
Operating Cash Flow changed +837% YoY in FY2025, a notable deviation from the 9-year average annual change of +132%.
Based on SEC 10-K filings.
$3.6B in FY2025 with a 5-year CAGR of +2.2%. Top quartile in the Health Care sector.
Improved from $3.5B to $3.6B over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -4.2%
- 5-Year CAGR
- +2.2%
- 10-Year CAGR
- -
Sector benchmark
Top 5% in Health CareTop 5% of 216This company $3.6B Sector average $658.7M
▼
+451.3% above sector average
Key checks
Key Insights
- 5-year CAGR of +2.2%, indicating consistent growth.
- In FY2025, operating cash flow increased 837.2% year-over-year.
- Ranks #11 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2022.
Company context
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.6B | +837.2% |
| FY2024 | -$492.6M | -113.9% |
| FY2023 | $3.5B | -14.3% |
| FY2022 | $4.1B | +56.2% |
| FY2021 | $2.6B | -18.7% |
| FY2020 | $3.3B | +107.3% |
| FY2019 | $1.6B | +23.5% |
| FY2018 | $1.3B | +50.3% |
| FY2017 | $844.9M | +257.9% |
| FY2016 | $236.1M | +164.6% |
As of FY2025 · SEC 10-K · Updated Mar 17, 2026